stockrow
Saturday 7 November 2026
Export JUNS’s income statement to Excel — free account
Jupiter Neurosciences, Inc.
JUNS Healthcare Biotechnology
Jupiter Neurosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21,800.00, down 90.7% from fiscal 2022.
- EPS
- +22.5%
- Free cash flow
- −177.1%
Quarter to June 2026, against a year earlier
2.27
0.14
+6.57%
Follow JUNS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (1,888.80%) | (6,530.06%) | (738.85%) | 266.88% |
+8 more TTM periods Free account |
|
| (239.36%) | (205.98%) | (146.94%) | (570.85%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
691.32% | 276.30% | 336.26% | 857.12% | |
Average Days of Receivables |
0.00 | — | 0.00 | — | |
Free Cash Flow per Share |
(13.00) | (12.33) | (11.75) | (14.89) | |
Free Cash Flow |
(7.25) | (5.78) | (5.41) | (6.74) | |
| Other line items | |||||
Cash ROIC |
(627.16%) | 1,374.24% | (276.58%) | (862.97%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(35.95) | (50.89) | (134.98) | (337.95) | |
Operating CF/Net income |
0.79 | 0.63 | 0.63 | 0.89 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(13.00) | (12.33) | (11.75) | (14.89) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates